New trials, publications, preprints and grants on this target, month by month.
Trial
Risk-reducing Strategies, Including Fimbriectomy, in Women With a Germline Mutation Predisposing to Ovarian or Pelvic Cancer
1 Mar 2027· NA · NOT_YET_RECRUITING· CTGOV
Trial
Vilastobart+Retifanlimab in BRCA or PALB2 Deficient PC
1 Jan 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Longitudinal Pancreatic Imaging Findings in BRCA1, BRCA2, ATM, and PALB2 Heterozygotes Undergoing Pancreatic Cancer Surveillance: A Prospective PRECEDE Consortium Study.
3 Nov 2026· JCO precision oncology· PUBMED
Publication
Case Report: Isolated leptomeningeal relapse after systemic control in PALB2-altered pancreatic cancer.
12 Oct 2026· Frontiers in medicine· PUBMED
Publication
A Heterogeneous Phenotypic Presentation of a PALB2 Mutation Carrier With Multiple Metachronous Primary Malignancies: A Case Report.
31 Aug 2026· Cureus· PUBMED
Publication
Age-Specific Ovarian Cancer Risk Among Individuals With Pathogenic Variants in PALB2.
26 Aug 2026· JCO precision oncology· PUBMED
Publication
Durable response to olaparib plus continued PD-1 blockade in germline PALB2-mutated triple-negative breast cancer with leptomeningeal metastasis: A case report.
21 Aug 2026· Medicine· PUBMED
Publication
Germline PALB2 Genetic Variant Associated with Rapid Metastatic Progression and Poor Survival in Two Kazakh Women with Breast Cancer: A Case Study.
31 Jul 2026· Genes· PUBMED
Publication
Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.
1 Jun 2026· JAMA oncology· PUBMED
Publication
A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
1 May 2026· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publication
Investigating the contribution of rare non-coding variants in BRCA1, BRCA2 and PALB2 to hereditary breast cancer.
4 Apr 2026· NPJ breast cancer· PUBMED
Publication
High Prevalence of Non-BRCA Pathogenic Variants and a Recurrent PALB2 Variant in an Argentine Hereditary Breast and Ovarian Cancer Cohort.
1 Apr 2026· Cancer medicine· PUBMED
Publication
Unique social, identity, and community factors impact prophylactic surgery discussions in young adults who are BRCA1, BRCA2, and PALB2 positive.
1 Apr 2026· Journal of genetic counseling· PUBMED
Publication
A comprehensive and accessible model for co-segregation analysis in BRCA1, BRCA2, and PALB2 variant classification.
26 Mar 2026· Human genetics· PUBMED
Publication
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada.
11 Mar 2026· Annals of surgical oncology· PUBMED
Publication
BRCA1/2, PALB2 mutations and first-line CDK4/6 inhibitor efficacy in HR+ metastatic breast cancer.
16 Feb 2026· Breast (Edinburgh, Scotland)· PUBMED
Publication
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
28 Jan 2026· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publication
Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma.
18 Jan 2026· Pediatric blood & cancer· PUBMED
Publication
Characterization of Copy Number Variants in Hereditary Cancer Patients Through NGS Shows a Distinctive PALB2 Contribution to the Diagnostic Yield.
3 Jan 2026· Human mutation· PUBMED
Trial
Population Based Germline Testing for Early Detection and Prevention of Cancer
18 Dec 2025· NA · RECRUITING· CTGOV
Publication
Alliance A022106: A Phase II/III Trial of Nab-Paclitaxel and Gemcitabine ± Cisplatin as Second-Line Treatment for BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM).
31 Oct 2025· JCO oncology advances· PUBMED
Trial
Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer
10 Jun 2025· PHASE2_PHASE3 · ACTIVE_NOT_RECRUITING· CTGOV
Trial
COMPRENDO - A PHASE II OPEN LABEL STUDY FOR THE COMPREHENSIVE ANALYSIS OF PREDICTORS OF THE TREATMENT WITH PEMBROLIZUMAB AND OLAPARIB IN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2 NEGATIVE BREAST CANCER AND A DELETERIOUS GERMLINE MUTATION IN BRCA1/2, ATM, BARD1, CHEK2, FANCC, PALB2, RAD51C, RAD51D, SLX4, XRCC2 OR A HOMOLOGOUS RECOMBINATION DEFICIENCY
28 Nov 2024· PHASE2 · COMPLETED· CTIS
Trial
Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies
21 Nov 2024· PHASE1 · RECRUITING· CTGOV
Trial
A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
1 Nov 2024· PHASE1 · NOT_YET_RECRUITING· CTGOV